Advertisement
Chairman and CEO Ed Quilty said, "The clinical outcomes evidence generatedthus far for MEDIHONEY since the product's launch late last year has beenexceptional. It is now becoming clear that the dressings are beginning toserve an important role as clinicians' first choice for wounds that have notprogressed with standard care, making up roughly 50% of all chronic wounds.The eleven posters being presented at the WUWHS showcase the variety of woundtypes being treated successfully with MEDIHONEY. This evidence, combined withthe satellite symposium, should have great impact on the conference attendees,and will contribute to the ramp up of global sales of the product."
Advertisement
The Satellite Symposium, taking place on Saturday, June 7 at 12:45 pm, istitled "The Antimicrobial and Wound Healing Effectiveness of ActiveLeptospermum Honey: Mechanisms of Action and Review of Current Evidence." Thesymposium will feature a lecture by Dr. Rose Cooper, PhD, Professor inMicrobiology, University of Wales Institute, Cardiff, UK, as well as a lectureby Dr. Georgina Gethin, PhD, RGN, DipHE Wound Care Lecturer at the ResearchCentre of Clinical Nursing and Midwifery, Royal College of Surgeons, Ireland.Dr. Cooper will present information on the mechanisms of action of ActiveLeptospermum Honey, as well as her findings on activity against biofilms andthe inability of organisms to select for resistance. Dr. Gethin will presentclinical evidence derived from her randomized controlled study comparing theantimicrobial activity and wound healing effectiveness of Active LeptospermumHoney against a standard advanced wound care dressing, as well as evidencefrom her study on Active Leptospermum Honey's effect on pH modulation onchronic wounds.
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advancedwound-care products. Its key product, MEDIHONEY, is sold throughout the worldby Derma Sciences and Comvita New Zealand -- the licensor of the patentedhoney-based technology -- and is the leading brand of honey-based dressingsfor the management of wounds and burns. The product has been shown to beeffective in a variety of wounds and burns, and was recently the focus of alarge-scale randomized controlled trial on leg ulcers. Derma has two productsin development: the NIMBUS technology based line of barrier gauze dressings,and DSC127, the company's novel angiotensin analog for accelerated woundhealing and scar reduction. The barrier technology was licensed from Quick-Medin Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 waslicensed from The University of Southern California in Q4 of 2007 and isentering into a Phase II study, with anticipated initial patient enrollment tobegin in Q3 of 2008. For more information about Derma Sciences, Inc., visitits home page on the Internet at http://www.dermasciences.com.
About the WUWHS
The World Union of Wound Healing Societies is a consortium of associationswith a single mission: to enhance the lives of persons with wounds worldwide.The WUWHS executives includes opinion leaders in wound care from Australia,Belgium, Canada, France, Denmark, the United Kingdom and the United States.Wound care profes
